|Bid||8.40 x 1000|
|Ask||8.45 x 1000|
|Day's range||8.25 - 9.06|
|52-week range||2.84 - 45.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||14 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||20.00|
Every investor in Longeveron Inc. ( NASDAQ:LGVN ) should be aware of the most powerful shareholder groups. Large...
MIAMI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging. This peer-reviewed article describes the design of the trial which investigated Lomec
Investors are reacting positively to the beginning of an Alzheimer's disease trial with Longeveron's lead candidate, Lomadel-B.